Long-term outcomes of nonmyeloablative autologous hematopoietic stem cell transplantation in multiple sclerosis

Nikolaev, I.; Fedorenko, Denis A.; Виноградов, О. И.; Kuznetsov, A.

doi:10.1016/j.jns.2019.10.842

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several international academic societies have recognized its important role in the treatment of people with MS ( 2 , 3 ), mainly in the more inflammatory variants of the disease (relapsing-remitting MS). We and others have been researching this area in recent years ( 4 – 8 ). After gaining experience conducting both auto and allografts in persons with hematological diseases in the HSCT programs in Puebla and Monterrey ( 9 ), we engaged in autografting patients with autoimmune conditions.…”

Section: Introductionmentioning

confidence: 99%

The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge

et al. 2021

View full text Add to dashboard Cite

After gaining experience conducting both auto and allografts in persons with hematological diseases in the HSCT programs in Puebla and Monterrey, México, this study outlines subsequent program autografting patients with autoimmune conditions. The first transplant in multiple sclerosis was conducted in Puebla on July 5, 2006. From 2015 we increased activity autografting persons with autoimmune conditions in the two campuses of the HSCT-México program: Puebla and Monterrey. By December 6, 2020, patient number 1,000 in the program was autografted. In our experience, a significant reduction in the expanded disability status scale score was achieved in all of the three phenotypes of the disease (from a median of 5.1 to 4.5 points), whereas the response rate (defined as a decrease of at least 0.5 of EDSS score regardless of baseline EDSS, or unchanged EDSS) was 83, 78, and 73% after 12 months in the relapsing-remitting, primary-progressive and secondary-progressive forms of multiple sclerosis, respectively. In addition to analyzing the viability, safety, and efficacy of our method, this study contributes new knowledge to the field of both stem cell transplantation and multiple sclerosis.

show abstract